Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

A Neurodegenerative Disorder-Alzheimer Disease: A Treatise


Affiliations
1 Kalyani Charitable Trust's R.G. Sapkal College of Pharmacy, Sapkal Knowledge Hub. Anjaneri, Trimbakeshwar, Nashik 422 212, India
     

   Subscribe/Renew Journal


Alzheimer disease (AD), though not a life threatening disease but increase the morbidity rate of an individual. It can be very well correlated with the retrograde amnesia. But specifically as it is encountered in elder subjects, it is represented as Senile Dementia. The earliest observable symptoms are often mistakenly thought to be 'age-related' concerns, or manifestations of stress. In the early stages, the most commonly recognized symptom is memory loss, such as difficulty in remembering recently learned facts. When a doctor or physician has been notified, and AD is suspected, the diagnosis is usually confirmed with behavioral assessments and cognitive tests, often followed by a brain scan if available. As the disease advances, symptoms include confusion, irritability and aggression, mood swings, language breakdown and long-term memory loss is also assumed. Gradually, bodily functions are lost, ultimately leading to death. It is found that some plaque is present in the brain. One area of clinical research is focused on treating the underlying disease pathology by reduction of amyloid beta levels is a common target of compounds under investigation. Immunotherapy or vaccination for the amyloid protein is one treatment modality under study. Unlike preventative vaccination, the putative therapy would be used to treat people already diagnosed.

Keywords

Alzheimer Disease, β-amyloid.
Subscription Login to verify subscription
User
Notifications
Font Size


  • McKhann G, Drachman DA, Folstein M, Katzman R, Price D, and Stadlan EM. Clinical diagnosis of Alzheimer's disease. Neurology 1984; 34: 939-944.
  • Petersen RC, Smith GE, Waring SC, Ivnik R, Tangalos, EG, and Kokmen, E. Mild cognitive impairment. Clinical characterization and outcome. Arch. Neurol. 1999; 56: 303-308.
  • Katzman R. The prevalence and malignancy of Alzheimer disease. Arch. Neurol. 1976; 33: 217-218.
  • Bowen DM, Smith CB, White P, and Davison AN. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other a biotrophies. Brain. 1976; 99: 459-496.
  • Davies P and Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976; 2: 1943.
  • Perry EK. Gibson PH, Blessed G, Perry RH, and Tomlinson BE. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necroscopy brain tissue. J.Neurol.Sci. 1977; 34: 247-265.
  • Wenk GL. Neuropathologic Changes in Alzheimer's disease. J.Clin.Psychiatry. 2003; 64(9): 7-10.
  • Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Discovery. 2006; 5(2): 160-170.
  • Palmer AM, Wilock GK, Esiri MM, Francis, PT and Bowen DM. Monoaminergic innervation of the frontal and temporal lobes in alzheimer's disease. Brain Res. 1987; 401: 231-238.
  • Leake A, Moore PB, Leitch M., Ayre K, Perry RH, Ince PG, Ferrier IN. The serotonergic system in Alzheimer's disease and normal neocortical post mortem brain: neurochemical and clinical correlates. Neurol. Psychar. Brain Res. 1993; 2: 53-59.
  • Yates CM, Simpson J, Gordon A, Maloney AFJ, Allison Y, Ritchie IM, and Urquhart A. Catecholamine and cholinergic enzymes in pre senile and senile Alzheimer type dementia and Down's syndrome. Brain Res. 1983; 280: 119-126.
  • Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P. Greengard P. and Buxbaum, JD. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 2000; 283: 1571-1577.
  • Chen GQ, Chen KS, Knox J, Inglis J, Bernard A, Martin SJ, Justice A, McConlogue L, Games D, Freedman SB and Morris RG. A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease, Nature. 2000; 408: 975-979.
  • The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's disease. In Consensus recommendations for the post-mortem diagnosis of Alzheimer's disease. Neurobiol. Aging. 1997; 18: S1-S2.
  • Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L and Yager D et al., Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP, Science. 2001; 293: 1487-1491.
  • Citron M. Alzheimer's disease: Treatments in discovery and development, Nat. Neurosci. 2002; 5: 1055-1057.
  • DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM and Holtzman DM, Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease, Proc. Natl. Acad. Sci. USA. 2001; 98: 8850-8855.
  • Diagnostic and statistical manual of mental disorders, 4th ed. DSMIV. Washington, D.C.: American Psychiatric Association, 1994.
  • Kawas CH. Early Alzheimer's disease. N Engl J Med 2003; 349: 1056-63.
  • Knopman DS, DeKosky ST, and Cummings JL, et al. Practice parameter: Diagnosis of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1143-53.
  • Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001; 286: 2120-7.
  • The American Association for Geriatric Psychiatry published a consensus statement on Alzheimer's treatment in 2006.
  • Cummings JL, Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry. 1998; 6: S64-78.
  • Perry EK, Perry RH, Blessed G, Tomlinson BE. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1977; 1: 189.
  • Mesulam MM, Guillozet A, Shaw P, Levey A, Duysen EG, Lockridge O. Acetyl cholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 2002b; 110: 627-39.
  • Scarpioi E, Scheltens P, Feldman H. Treatment of Alzheimer's disease: Current status and new perspectives. Lancet Neurol 2003; 2: 539-47.
  • Loy C, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev 2004, CD001747.
  • Birks JS, Harvey R. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst. Rev 2003; CD001190.
  • Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, Van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: Systematic review of randomized clinical trials. BMJ 2005; 331: 321-7.
  • Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int. 2004; 45: 583-95.
  • Kornhuber J, Weller M. Psychotogenicity and N-methyl-d-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 1997; 41: 135-44.
  • Javitt DC. Glutamate as a therapeutic target in psychi atric disorders. Mol Psychiatry 2004; 9: 984-97-979.
  • Areosa Sastre A, Sherriff F, McShane R. Memantine for dementia (Cochrane Review). Cochrane Database Syst Rev 2005; 2.
  • Hood WF, Sun ET, Compton RP, Monahan JB. 1-aminocyclobutane 1-carboxylase (ACBC): A specific antagonist of the N-methyl-d-aspartate receptor coupled glycine receptor. Eur.J.Pharmacol. 1989; 161: 281-282.
  • Honore T, Davies SN, Drejer J, Fletcher EJ, Jacobsen P, Lodge D, and Nielsen FE. Quinoxalinediones: potent competitive non NMDA glutamate receptor antagonist.Science. 1988; 241: 701-703.
  • Alzheimer A. Ueber eigenartige Krankheitsfaelle des spaeteren lters. Zeitschrift fuer die Gesamte Neurologie und Psychiatrie 1911; 4: 356-85.
  • Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron. 1991; 6: 487-98.
  • Glenner GG, Wong CW. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984; 120: 885-90.
  • Terry RD. The fine structure of neurofibrillary tangles in Alzheimer's disease. J Neuropathol Exp Neurol 1963; 22: 629-42.
  • Wischik CM, Novak M, Thogersen HC, Edwards PC, Runswick MJ, Jakes R, et al. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci USA 1988; 85: 4506-10.
  • Sergeant N, Bussiere T, Vermersch P, Lejeune JP, Delacourte A. Isoelectric point differentiates PHF-tau from biopsy-derived human brain tau proteins. Neuroreport 1995; 6: 2217-20.
  • Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-6
  • Murrell J, Farlow M, Ghetti B, Benson MD. A. mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 1991; 254: 97-9.
  • Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995; 375: 754-60.
  • Cruts M, Rademakers R. Alzheimer Disease & Front temporal Dementia Mutation Database. Available at: http://www.molgen.ua.ac.be/AD Mutations/. Accessed 2006.
  • Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987; 325: 733-6.
  • Oltersdorf T, Ward PJ, Henriksson T, Beattie EC, Neve R, Lieberburg I, et al. The Alzheimer amyloid precursor protein. Identification of a stable intermediate in the biosynthetic/degradative pathway. J Biol Chem 1990; 265: 4492-7.
  • Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al. A subset of NSAIDs lower amyloidogenic A beta 42 independently of cyclooxygenase activity. Nature 2001; 414: 212-6.
  • Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, et al. Dramatic aggregation of Alzheimer A beta by Cu (II) is induced by conditions representing physiological acidosis. J Biol Chem 1998; 273: 12817-26.
  • Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001; 30: 665-76.
  • Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-7.
  • Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, et al. Epitope and isotype specificities of antibodies to betaamyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci. USA 2003; 100: 2023-8.
  • Buttini M, Masliah E, Barbour R, Grajeda H, Motter R, Johnson-Wood K, et al. Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci. 2005; 25: 9096-101.
  • Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging. 1995; 16: 271-84.
  • Alonso AC, Zaidi T, Grundke-Iqbal I, Iqbal K. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci USA 1994; 91: 5562-6.
  • Mandelkow EM, Mandelkow E. Tau in Alzheimer's disease. Trends Cell Biol 1998; 8: 425-7.
  • Johnson GVV, Hartigan JA. Tau protein in normal and Alzheimer's disease brain: an update. Alzheimer's Dis Rev 1998; 3: 125-141.
  • Tuppo EE, Arias HR. The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol 2005; 37: 289-305.
  • Szekely CA, Thorne JE, Zandi PP, Ek M, Messias E, Breitner JC, et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology. 2004; 23: 159-69.
  • Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 1998; 95: 6460-4.
  • Cordy JM, Hussain I, Dingwall C, Hooper NM, Turner AJ. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc Natl Acad Sci USA 2003; 100: 11735-40.
  • Wolozin B. Cholesterol and the biology of Alzheimer's disease. Neuron 2004; 41: 7-10.
  • Wolozin B, Manger J, Bryant R, Cordy J, Green RC, McKee A. Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Acta Neurol Scand Suppl 2006; 185: 63-70.

Abstract Views: 390

PDF Views: 2




  • A Neurodegenerative Disorder-Alzheimer Disease: A Treatise

Abstract Views: 390  |  PDF Views: 2

Authors

V. V. Buchake
Kalyani Charitable Trust's R.G. Sapkal College of Pharmacy, Sapkal Knowledge Hub. Anjaneri, Trimbakeshwar, Nashik 422 212, India
A. P. Muthal
Kalyani Charitable Trust's R.G. Sapkal College of Pharmacy, Sapkal Knowledge Hub. Anjaneri, Trimbakeshwar, Nashik 422 212, India
R. B. Saudagar
Kalyani Charitable Trust's R.G. Sapkal College of Pharmacy, Sapkal Knowledge Hub. Anjaneri, Trimbakeshwar, Nashik 422 212, India
R. S. Bachhav
Kalyani Charitable Trust's R.G. Sapkal College of Pharmacy, Sapkal Knowledge Hub. Anjaneri, Trimbakeshwar, Nashik 422 212, India

Abstract


Alzheimer disease (AD), though not a life threatening disease but increase the morbidity rate of an individual. It can be very well correlated with the retrograde amnesia. But specifically as it is encountered in elder subjects, it is represented as Senile Dementia. The earliest observable symptoms are often mistakenly thought to be 'age-related' concerns, or manifestations of stress. In the early stages, the most commonly recognized symptom is memory loss, such as difficulty in remembering recently learned facts. When a doctor or physician has been notified, and AD is suspected, the diagnosis is usually confirmed with behavioral assessments and cognitive tests, often followed by a brain scan if available. As the disease advances, symptoms include confusion, irritability and aggression, mood swings, language breakdown and long-term memory loss is also assumed. Gradually, bodily functions are lost, ultimately leading to death. It is found that some plaque is present in the brain. One area of clinical research is focused on treating the underlying disease pathology by reduction of amyloid beta levels is a common target of compounds under investigation. Immunotherapy or vaccination for the amyloid protein is one treatment modality under study. Unlike preventative vaccination, the putative therapy would be used to treat people already diagnosed.

Keywords


Alzheimer Disease, β-amyloid.

References